NEW YORK, NY, April 27, 2026

TytoCare has achieved a major regulatory milestone with the U.S. Food and Drug Administration granting De Novo classification for its AI-powered ENT diagnostic solution, marking the first FDA-cleared artificial intelligence system designed to analyze otoscopy video recordings of the eardrum. This approval establishes an entirely new regulatory category for AI-driven ear, nose, and throat (ENT) image analysis, positioning TytoCare at the forefront of next-generation digital diagnostics and remote healthcare innovation.

FDA De Novo Creates New AI Diagnostic Category

The FDA De Novo classification represents a groundbreaking regulatory achievement, as it creates a new device classification for “ENT image analyzers” powered by artificial intelligence, paving the way for future innovations in AI-assisted diagnostics. TytoCare’s Tyto Insights™ for ENT Suite leverages advanced machine learning algorithms to detect eardrum bulging, a key clinical indicator of acute otitis media and other ear-related conditions.

By analyzing otoscopic video recordings captured through TytoCare’s connected digital otoscope, the system provides clinical decision support to healthcare providers while simultaneously informing patients about their condition, enhancing both diagnostic accuracy and patient engagement. This innovation is particularly significant given that ear infections account for nearly 20 million physician visits annually in the United States, highlighting the urgent need for scalable and accurate diagnostic solutions.

AI-Powered Remote Care Enhances Clinical Accuracy

Advertisement

cGxPJobs Banner

TytoCare’s AI solution is built on a proprietary dataset of over 1.6 million ear images and recordings, enabling highly accurate and consistent detection of abnormalities. The integration of AI with remote examination tools addresses a major limitation in telehealth, where visual assessment of the eardrum has traditionally been challenging.

The system is designed for patients aged six months and older, making it highly relevant for pediatric care, where ear infections are most prevalent. By enabling early and accurate detection of eardrum bulging, the technology can help reduce unnecessary antibiotic prescriptions and improve treatment timelines, ultimately contributing to better patient outcomes and antimicrobial stewardship.

The addition of Smart Checkup capabilities within TytoCare’s platform further enhances patient engagement, providing actionable insights from ear and lung examinations and supporting more informed clinical decision-making. This aligns with the broader healthcare shift toward patient-centered, data-driven care delivered outside traditional clinical settings.

Expanding Access to High-Quality Virtual Healthcare

This regulatory milestone reinforces TytoCare’s mission to bring comprehensive, high-quality healthcare into the home, addressing critical challenges such as limited access to primary care and increasing demand for remote diagnostics. Through its Home Smart Clinic and Pro Smart Clinic solutions, the company enables remote examinations across multiple systems, including the heart, lungs, throat, ears, and skin.

The integration of AI-powered diagnostic support tools represents a transformative step in scaling healthcare delivery, allowing clinicians to make more accurate diagnoses without requiring in-person visits. This is particularly important in the context of a growing shortage of primary care physicians, where technology-driven solutions can help bridge gaps in access and improve efficiency across healthcare systems.

From a cGxP perspective, the FDA De Novo pathway underscores the importance of rigorous validation, regulatory compliance, and quality assurance in the development of AI-based medical devices, ensuring that such technologies meet high standards for safety, effectiveness, and reliability. The establishment of a new regulatory category also sets a precedent for future AI-driven diagnostic tools, accelerating innovation while maintaining strict oversight.

Source: TytoCare press release